Sidansai Biotechnology Co., Ltd. (abbreviated as Sidansai) is positioned to become a global leader in cell therapy, stem cell therapy, and regenerative medicine, dedicated to serving technological innovation and human health. As one of the global CAR-T therapy enterprises, Sidansai has collaborated with many renowned top-tier hospitals across China to conduct CAR-T clinical trials, completing clinical research on 26 cases of relapsed/refractory leukemia, with 23 patients achieving complete remission, a complete remission rate of 88%.
To expand into overseas markets, Sidansai's English name has been officially changed to Innovative Cellular Therapeutics (website: ), abbreviated as ICT. ICT signifies innovative cellular therapy, reflecting Sidansai's ambition to continually achieve innovative results in the international cell therapy field and benefit human health. Currently, the development of cell therapy is timely, and we welcome everyone to join us in creating a better future.
Sidansai sincerely invites you to join us. For more details about Sidansai, please visit our website:
Provided by
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows
Jobui does not provide an APP. Please follow our WeChat official account.
